Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
This was a 52-week trial with a 26-week extension among children (10 17 years of age) with uncontrolled T2D (HbA1c 6.5 - 10.5%) receiving metformin, insulin, or both
CXCR2 chemokine receptora master regulator in cancer and physiology
The introduction of oral formulations, such as oral semaglutide approved in 2019, has improved patient convenience and adherence by eliminating the need for injections
VPA-exposed rats (Fig
Zhao, T., et al., HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs
US$ 26.60
US$ 20.42
US$ 20.14
